Keywords
Genitourinary syndrome
Vaginal atrophy
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To describe the scientific evidence regarding the use of vaginal laser therapy in genitourinary syndrome of menopause, assessing its efficacy and impact on quality of life. Methods: A literature review was conducted in scientific databases (BVS, PubMed, and SciELO) from May to August 2025, using the MeSH descriptors “Vaginal Atrophy,” “Lasers, Medical,” “Postmenopause,” and “Menopause.” Free full-text articles published in the last five years in English, Portuguese, or Spanish were included. Results: Vaginal laser therapy (CO₂ and Er:YAG) appears to be a promising treatment for genitourinary syndrome of menopause, improving symptoms such as vaginal dryness, pain, and dyspareunia, as well as sexual function, through stimulation of collagen production and tissue vascularization. Evidence supports its short-term safety and effectiveness; however, robust long-term data are lacking, and limitations include high costs and the absence of standardized treatment protocols. Final Considerations: Vaginal laser therapy represents an innovative and safe alternative for managing genitourinary syndrome of menopause, particularly in women with contraindications to hormonal therapy. Further long-term studies, protocol standardization, and cost-effectiveness analyses are necessary to support its widespread clinical use.
References
ASHRAF AB, et al. Genitourinary syndrome of menopause: a multicenter study from the Indian Midlife Registry. Climacteric, 2025; 28(3): 329-336.
CREAN-TATE KK, et al. Management of genitourinary syndrome of menopause in female cancer patients: a focus on vaginal hormonal therapy. American journal of obstetrics and gynecology, 2020; 222(2): 103-113.
FAUBION SS, et al. Genitourinary syndrome of menopause: management strategies for the clinician. In: Mayo Clinic Proceedings. Elsevier, 2017; 1842-1849.
GABRIELI D, et al. “Modified Schirmer Test” as an Objective Measurement for Vaginal Dryness: A Prospective Cohort Study. Diagnostics, 2022; 12(3): 574.
GANDHI J, et al. Genitourinary syndrome of menopause: an overview of clinical manifestations, pathophysiology, etiology, evaluation, and management. American journal of obstetrics and gynecology, 2016; 215(6): 704-711.
GASPAR A, et al. Vaginal fractional CO2 laser: a minimally invasive option for vaginal rejuvenation. The American Journal of Cosmetic Surgery, 2011; 28(3): 156-162.
GHANBARI Z, et al. Vaginal CO2 Fractional Laser in Women With Vaginal Atrophy: Medical Insights on Short-and Long-term Effects on Genitourinary Symptoms. Journal of Lasers in Medical Sciences, 2024; 15: e59.
GOLD D, et al. Vaginal laser therapy versus hyaluronic acid suppositories for women with symptoms of urogenital atrophy after treatment for breast cancer: a randomized controlled trial. Maturitas, 2023; 167: 1-7.
HYMPANOVA L, et al. The ewe as an animal model of vaginal atrophy and vaginal Er: YAG laser application. Menopause, 2021; 28(2): 198-206.
JABER S, et al. CO2 Laser Therapy for Genitourinary Syndrome of Menopause in Women with Breast Cancer: A Randomized, Sham-Controlled Trial. Cancers, 2025; 17(7): 1241.
KAPLAN I, et al. GER R. The treatment of erosions of the uterine cervix by means of the CO2 laser. Obstetrics & Gynecology, 1973; 41(5): 795-796.
KINGSBERG SA, et al. The women's EMPOWER survey: identifying women's perceptions on vulvar and vaginal atrophy and its treatment. The journal of sexual medicine, 2017; 14(3): 413-424.
MAC BRIDE MB, et al. Vulvovaginal atrophy. In: Mayo Clinic Proceedings. Elsevier, 2010; 87-94.
MACHADO AC, et al. Applicability of vaginal energy-based devices in urogynecology: evidence and controversy. Revista da Associação Médica Brasileira, 2023; 69(suppl 1): e2023S129.
MARINO JM. Genitourinary syndrome of menopause. Journal of midwifery & women's health, 2021; 66(6): 729-739.
MERLINO L, et al. Therapeutic choices for genitourinary syndrome of menopause (GSM) in breast cancer survivors: a systematic review and update. Pharmaceuticals, 2023; 16(4): 550.
NAPPI RE, KOKOT-KIEREPA M. Vaginal Health: Insights, Views & Attitudes (VIVA)–results from an international survey. Climacteric, 2012; 15(1): 36-44.
PARAISO MFR, et al. A randomized clinical trial comparing vaginal laser therapy to vaginal estrogen therapy in women with genitourinary syndrome of menopause: The VeLVET Trial. Menopause, 2020; 27(1): 50-56.
PARDO J, et al. Laser labioplasty of labia minora. International journal of gynecology & obstetrics, 2006; 93(1): 38-43.
PHILLIPS NA, BACHMANN GA. The genitourinary syndrome of menopause. Menopause, 2021; 28(5): 579-588.
PINHO SC, et al. Efficacy of fractional laser on steroid receptors in GSM patients. Bioengineering, 2023; 10(9): 1087.
PRODROMIDOU A, et al. CO2 laser versus sham control for the management of genitourinary syndrome of menopause: a systematic review and meta-analysis of randomized controlled trials. Journal of Personalized Medicine, 2023; 13(12): 1694.
QUICK AM, et al. Long-term follow-up of fractional CO2 laser therapy for genitourinary syndrome of menopause in breast cancer survivors. Journal of Clinical Medicine, 2022; 11(3): 774.
TADIR Y, et al. Energy-based treatment for gynecologic conditions including genitourinary syndrome of menopause: consensus, controversies, recommendations, and FDA clearance. Lasers in surgery and medicine, 2019; 51(4): 315-317.
U.S. Food and Drug Administration. Product classification. Disponível em: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpcd/classification.cfm?ID561299.
U.S. Food and Drug Administration (2018) Statement from FDA Commissioner Scott Gottlieb, M.D., on Efforts to Safeguard Women’s Health from Deceptive Health Claims and Significant Risks Related to Devices Marketed for Use in Medical Procedures for “Vaginal Rejuvenation”. Disponível em: https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-efforts-safeguard-womens-health-deceptive-health-claims.
WOŹNIAK A, et al. Efficacy of Fractional CO2 Laser Treatment for Genitourinary Syndrome of Menopause in Short-Term Evaluation—Preliminary Study. Biomedicines, 2023; 11(5): 1304.
WOŹNIAK S, WOŹNIAK A. Assessing the Long-Term Effectiveness of Fractional CO2 Laser Treatment in Perimenopausal Women with Genitourinary Syndrome of Menopause—Single Center Preliminary Study. Journal of Clinical Medicine, 2025; 14(1): 242.